Join Growin Stock Community!

Larimar therapeutics, inc.LRMR.US Overview

US StockHealthcare
(No presentation for LRMR)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

LRMR AI Insights

LRMR Overall Performance

LRMR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

LRMR Recent Performance

-1.18%

Larimar therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

LRMR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

LRMR Key Information

LRMR Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

LRMR Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Price of LRMR

LRMR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

LRMR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.54
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
3.30
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.54
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
3.30
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is LRMR's latest earnings report released?

    The most recent financial report for Larimar therapeutics, inc. (LRMR) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LRMR's short-term business performance and financial health. For the latest updates on LRMR's earnings releases, visit this page regularly.

  • How much debt does LRMR have?

    As of the end of the reporting period, Larimar therapeutics, inc. (LRMR) had total debt of 4.35M, with a debt ratio of 0.02. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does LRMR have?

    At the end of the period, Larimar therapeutics, inc. (LRMR) held Total Cash and Cash Equivalents of 90.75M, accounting for 0.48 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is LRMR's EPS continuing to grow?

    According to the past four quarterly reports, Larimar therapeutics, inc. (LRMR)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.61. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of LRMR?

    Larimar therapeutics, inc. (LRMR)'s Free Cash Flow (FCF) for the period is -28.78M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 16.94% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.